GlassScriptPhysician profile
Robert Ryan Looney
NPI 1568807196
$2,645.02
in general payments reported to CMS, 2019-2025
22 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.32 · 2022: $571 · 2023: $752 · 2024: $774 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.53 | 2022-2025 | |
| Abbott Laboratories | $322.65 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $243.36 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $227.76 | 2022-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $225.54 | 2023-2025 | |
| Glaxosmithkline, LLC. | $186.31 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $139.21 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.02 | 2022-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $109.88 | 2022-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.14 | 2022-2025 | Synjardy, Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $63.26 | 2022-2023 | |
| Astellas Pharma US INC | $57.92 | 2024-2025 | Veozah |
| Mylan Specialty L.P. | $39.60 | 2022-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $35.28 | 2024 | |
| Daiichi Sankyo INC. | $32.76 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.70 | 2023-2024 | Repatha, Otezla |
| Medtronic, INC. | $28.53 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.98 | 2022 | |
| Insulet Corporation | $16.51 | 2023 | Omnipod |
| Phathom Pharmaceuticals, INC. | $15.46 | 2024 | Voquezna |
| Exact Sciences Corporation | $15.00 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Looney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.